ADVAC ALUMNI MEETING DURING SAGE

Slides:



Advertisements
Similar presentations
1 Welcome Safety Regulatory Function Handbook April 2006.
Advertisements

4 th Meeting of the EC International Dialogue on Bioethics Copenhagen, June 19 th, 2012 Large research and medical databases in clinical and research multi-centred.
IAEA International Atomic Energy Agency Introductions; Objectives and Scope of the Course Tr aining course on Authorization and Inspection of Uranium Mining.
Principles for clinical evaluation of vaccines: WHO guidelines
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
3rd WHO Prequalification Stakeholders Meeting
Good Participatory Practice (GPP) Guidelines for Biomedical HIV Prevention Trials Second Edition 2011.
INSAG DEVELOPMENT OF A DOCUMENT ON HIGH LEVEL SAFETY RECOMMENDATIONS FOR NUCLEAR POWER Milestone Issues: Group C. Nuclear Safety. A. Alonso (INSAG Member)
Regulatory Body MODIFIED Day 8 – Lecture 3.
Good Clinical Practice GCP
Internal Auditing and Outsourcing
Why companies saying or should say “YES” to India for Studies.
Clinical Research Conference 2012 Legal, Ethical, and Social Dimensions of Clinical Research Takis Vidalis, Ph. D., Hellenic National Bioethics Commission.
Who’s the Boss? Faculty Advisor or Principal Investigator Supervision versus Student Investigator or Study Coordinator Responsibilities Gwenn Snow, MS,
ECBS: Vaccines and Biotherapeutic products Dr Ivana Knezevic TSN/EMP/HIS WHO, Geneva, 31 st October 2013 EMP Technical Briefing Seminar EMP Technical Briefing.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Summary About me & AMRC About the EU Clinical Trials Regulation – what’s new Implementation timeline What does this mean for UK ethicists?
International Atomic Energy Agency Code of Conduct on the Safety and Security of Radioactive Sources Training Course on Technical Requirements to Fulfill.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
Bioequivalence and Bioavailability Working Group.
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
XXX_DECRIPT_MON00/1 Quality and impact of Social Science and Operations Research by the Special Programme in Human Reproduction Department of Reproductive.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
Main Requirements on Different Stages of the Licensing Process for New Nuclear Facilities Module 4.1 Steps in the Licensing Process Geoff Vaughan University.
R&D – a perspective Dr Nana Theodorou Research Coordinator Sheffield Clinical Research Office.
Characterizing evidence in EMF risk assessment, Berlin, 4-5 May 2006 The WHO International EMF Project Dr E. van Deventer Radiation and Environmental Health.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Regulatory Authority.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
IAEA International Atomic Energy Agency International Standards, Codes and Guidance for Radiation Safety Regulatory Infrastructure IAEA Advanced Regional.
Laboratory of Methods Development and Quality Control Laboratory Overview September 22, 2005.
International Atomic Energy Agency Roles and responsibilities for development of disposal facilities Phil Metcalf Workshop on Strategy and Methodologies.
WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies WHO Headquaters, Geneva, Switzerland 31 October - 4 November 2011 Alain PRAT, Technical.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
Ivana Knezevic | 1 |1 | PANDRH meeting, BTP session WHO Survey on Biotherapeutic Products (focus on clinical issues) Ottawa, 6 th September 2013 Dr Ivana.
An agency of the European Union Guidance on the anonymisation of clinical reports for the purpose of publication in accordance with policy 0070 Industry.
CLINICAL TRIALS.
Quality Assurance in Egypt and the European Standards and Guidelines
A capacity building programme for patient representatives
Recent Evolution of New Drug Review and Approval System in Korea
Responsibilities of Sponsor, Investigator and Monitor
The Importance of Ethical and Human Rights Issues in Global Health
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Community Participation in Research
IAEA Perspectives on Implementation of the optimization principle
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
The International Plant Protection Convention
Good Clinical Practice
Pharmacovigilance in clinical trials
Overview of vaccines prequalification
Quality and Qualifications Ireland and its Functions
CHIMS: What does it mean to be a responsible research funder?
WORKSHOP 17th Sept 2008 EUROPEAN COMMISSION
Communication and Consultation with Interested Parties by the RB
Nick Bonvoisin Secretary to the Convention on the
Rieke van der Graaf PhD UMC Utrecht, Julius Center
In Argentina Ana Palmero Legal and Research Ethics Advisor
Regulatory Perspective of the Use of EHRs in RCTs
DRAFT ISO 10008:2013 Overview Customer satisfaction — Guidelines for business-to-consumer electronic commerce transactions ISO/TC176 TG 01.
IAEA - Department of Nuclear Safety & Security
Presentation transcript:

ADVAC ALUMNI MEETING DURING SAGE WHO perspective on Human Challenge Trials in Vaccine Development and Licensing Dr Ivana Knezevic, WHO 23rd October 2018 Ivana Knezevic, WHO www.who.int

WHO standards and other services to facilitate regulatory oversight of vaccines in developing countries Facilitating registration (regulatory standards – Guidelines, Recommendations and measurement standards) Prequalification and emergency assessment procedures Collaborative procedures and joint assessments Vaccine safety initiatives 11/05/2019 WHO Guidelines

WHO norms and standards for biologicals Global written standards  Total 93 docs (Recommendations/ Guidelines) General docs that apply to vaccines & BTP: 10 General documents that apply to all vaccines: 12 Vaccine specific: 63 BTP specific: 8 Global measurement standards Scientific evidence Standardization of assays Further development and refinement of QC tests 3) Scientific basis for setting specifications www.who.int/biologicals Measurement standards: essential elements for development, licensing and lot release

Concept of WHO Guidelines 1) Provide key principles for evaluation of biologicals as a basis for setting national requirements; 2) Leave space to NRAs to formulate additional/ more specific requirements; 3) Living documents that will be developed further in line with the progress in scientific knowledge and experience 4) Assist with the implementation of the guidelines into regulatory and manufacturers practices through: Global, regional and national workshops involving regulators, manufacturers and other relevant experts Trainings, advisory groups 5) Consider guidance issued by other bodies – intention to complement them, not to create a conflict. 11/05/2019 WHO Guidelines

Vaccine Clinical Development Programs Immunogenicity Revised Guidelines on clinical evaluation of vaccines (TRS 1004, annex 9) Introduction Scope Glossary Vaccine Clinical Development Programs Immunogenicity Efficacy and effectiveness Safety Authors and Acknowledgements References 11/05/2019 WHO Guidelines

Scientific and regulatory considerations for HCT, TRS 1004, annex 10 (1) Not all diseases are suitable for "challenge-protection studies" Regulatory framework Quality and safety of pathogenic challenge strain GCP Various purposes for HCT in vaccine development: Often a type of efficacy indicating study Better understanding of pathogenesis of , and immunity to, the organism to guide decisions on immune responses that a vaccine might need to elicit in order to protect against disease 11/05/2019 WHO Guidelines

Scientific and regulatory considerations for HCT, TRS 1004, annex 10 (2) Various purposes for HCT in vaccine development (cont.): Proof of concept to identify potential ICP and other elements which will be then validated in an efficacy study Down or up selection of vaccine candidates Provision of a basis for licensure (rare case) Post-licensure studies to explore waning immunity, need for booster or duration of protection other 11/05/2019 WHO Guidelines

Scientific and regulatory considerations for HCT, TRS 1004, annex 10 (3) Study design of human challenge trials: the purpose of the study is influencing study design Different models according to the purposes and study design Challenge organism Usefulness for positive or negative prediction Operational aspects Relevant committees Qualified investigators Protocol Special facilities to prevent spread of challenge organism High level of control

Scientific and regulatory considerations for HCT, TRS 1004, annex 10 (4) Some key ethical considerations: Minimize risk to subjects and maximize benefits Review by an independent ethics committee Informed consent Other issues and references to more detailed sources of information 11/05/2019 WHO Guidelines

Quality and safety of challenge strains Strain characterization: Details like patient isolate, passage history etc Phenotype Genotype Purity Potency Stability Safety 11/05/2019 WHO Guidelines

Challenges identified by DCVRN Outcomes of survey of DCVRN representatives HCT have not been conducted in their countries WHO guidelines for regulators recognized as a standard Need for further assistance from WHO The following concerns were noted: safety of participants, risks of spreading challenge organism to the environment, availability of suitable care for (infected) participants, coercive (excessive) payments for participation, public perceptions of unsafe or unethical conduct - The need for Phase-3 studies to confirm HCT results 11/05/2019 WHO Guidelines

Challenges in the international context Lack of expertise and experience for reviewing HCT Responsibilities for oversight of HCT are not defined at the national level: Unclear role of various expert groups/ committees Lack of understanding role of regulators in HCT Infrastructure, CT sites, inspections Lack of trust in "experimental studies" Risk benefit analysis, RMP Lack of publicly available data due to lack of CT registration but also selected data for publication 11/05/2019 WHO Guidelines

Way forward Implementation workshops: At the global and regional level are very much needed Case studies and review of examples Topics of particular interest: Immune response to vaccines Quality of challenge strains Design of HCT Data from HCT in the context of licensing HCT as part of development of vaccines for PHE 11/05/2019 WHO Guidelines

Acknowledgements Rebecca Sheets and other authors of the report of the 1st IABS conference held in Oct 2014 Drafting group on clinical evaluation of vaccines – M. Powel (MHRA, UK), J. McEwen (TGA, Australia), V. Moorthy (WHO) Participants of WHO consultation held in July 2014: meeting report published in Vaccine 2015; 33 (17):1999-2003 11/05/2019 WHO Guidelines

WHO 20, Avenue Appia 1211 Geneva Switzerland Thank you WHO 20, Avenue Appia 1211 Geneva Switzerland Ivana Knezevic, WHO